Press Releases

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

September 17, 2020

Tags |  Corporate

Agreement will significantly increase global supply capacity for Lilly's potential COVID-19 treatments INDIANAPOLIS and THOUSAND OAKS, Calif. , Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to

Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care

September 15, 2020

Tags |  Corporate

INDIANAPOLIS , Sept. 15, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis.

Lilly Announces Leadership Changes

September 9, 2020

Tags |  Corporate

Patrik Jonsson named Senior Vice President, President of Lilly USA and Chief Customer Officer   Ilya Yuffa promoted to Senior Vice President and President of Lilly Bio-Medicines INDIANAPOLIS , Sept. 9, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that Patrik Jonsson ,

Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement

August 18, 2020

Tags |  Corporate

INDIANAPOLIS and SUZHOU, China , Aug. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Innovent Biologics, Inc. (HKEX: 01801) today announced a global expansion of their strategic alliance for TYVYT ® (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine

Central Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments

June 25, 2020

Tags |  Corporate

The fund, established by the Eli Lilly and Company Foundation, Lumina Foundation and Central Indiana Community Foundation, will focus on solutions that address racial inequities in the criminal justice system INDIANAPOLIS , June 25, 2020 /PRNewswire/ -- A coalition of local stakeholders has

Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice

June 13, 2020

Tags |  Corporate

Eli Lilly and Company commits 25,000 employee volunteer hours of service to help speed progress INDIANAPOLIS , June 13, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the

Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event

June 12, 2020

Tags |  Corporate

30-Minute Broadcasted Event on Saturday, June 13, at 12 p.m. EDT INDIANAPOLIS , June 12, 2020 /PRNewswire/ -- What: Eli Lilly and Company , Indianapolis Recorder Newspaper, Radio One and WISH-TV invite people and organizations to come together to acknowledge the trauma of racial injustice,

Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

May 4, 2020

Tags |  Corporate

SHANGHAI and INDIANAPOLIS , May 4, 2020 /PRNewswire/ -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

March 31, 2020

Tags |  Corporate

INDIANAPOLIS and OXFORD, England , March 31, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in

Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic

March 23, 2020

Tags |  Corporate

INDIANAPOLIS , March 23, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company will delay most new study starts and pause enrollment in most ongoing studies.